TB-500


Overview

TB-500 is a synthetic fragment of thymosin beta-4, a naturally occurring 43-amino-acid peptide present in virtually all human cells. It is the second pillar of the regenerative peptide world, usually discussed alongside BPC-157 — the famous Wolverine stack combines both.

Like BPC-157, the evidence base is almost entirely preclinical, though thymosin beta-4 itself has been in human trials for wound healing and cardiac repair.

How It Works

Thymosin beta-4 regulates actin, a protein fundamental to cell structure and movement. By modulating actin polymerization, it promotes cell migration to injury sites — the first step of tissue repair.

Broad regenerative signaling

The peptide also reduces inflammation, promotes angiogenesis, and inhibits fibrosis (scar tissue formation). This combination — more blood vessels, more repair cells, less scarring — explains its reputation for flexibility and range-of-motion improvements in chronically stiff tissues.

Key Benefits

Soft tissue repair — animal models show accelerated healing of muscle, tendon and ligament injuries.

Reduced fibrosis — less scar tissue means more functional, flexible healed tissue.

Cardiac repair — thymosin beta-4 has human trial data in heart attack recovery, the most advanced clinical evidence in this family.

Flexibility — the most consistently reported anecdotal benefit, likely from reduced adhesions.

Side Effects & Considerations

Human safety data for TB-500 specifically is lacking. The parent molecule has passed early-phase human trials without major signals, but that does not establish safety for chronic grey-market use.

The cancer question

Because thymosin beta-4 is involved in cell migration, researchers have studied its role in tumor metastasis. Evidence is mixed and unresolved — anyone with a personal or strong family history of cancer should treat this as a serious unknown. TB-500 is WADA prohibited and not approved for human use.

Dosage protocols

Protocol Dosage Frequency Duration Notes
Loading (anecdotal) 2-2.5 mg Twice weekly 4-6 weeks Subcutaneous. Community convention — no human dosing studies exist.
Maintenance 2 mg Once weekly or biweekly As needed Used after the loading phase for chronic issues.

Warnings

No approved human use. WADA prohibited. Unresolved theoretical concerns regarding cell migration and cancer.